Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4201-4210 Newer>

The Motley Fool October 5, 2007 Brian Orelli	Merck's Next Blockbuster? Merck's cholesterol drug comes back from phase 2 testing with no side effects. Investors, take note.
The Motley Fool October 4, 2007 Brian Orelli	Stopping the Inflammation Johnson & Johnson subsidiary Centocor announces positive phase 3 data for its psoriasis drug. Given the strong results from the trial, the company plans to file a marketing application for the drug by the end of the year.
The Motley Fool October 4, 2007 Billy Fisher	Isis Keeps Cholesterol Down, Stock Prices Up Isis Pharmaceuticals reports positive phase 2 results for a cholesterol treatment. The company continues to show progress with its impressive pipeline of 17 other development-stage drugs. Investors, take note.
The Motley Fool October 4, 2007 Billy Fisher	Immucor Draws First Blood The blood-testing equipment maker sees double-digit growth in both sales and earnings in Q1.
The Motley Fool October 3, 2007 Brian Lawler	FDA Says Nay to Endo Endo Pharmaceuticals announces that the FDA issued a "not approvable" letter in response to the company's attempt to expand the label for migraine treatment Frova.
The Motley Fool October 3, 2007 Brian Orelli	Big Pharma Loves Your Liver Three big pharma companies, AstraZeneca, GlaxoSmithKline, and Roche, are funding a stem-cell consortium. Investors, take note.
The Motley Fool October 2, 2007 Brian Orelli	Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data.
The Motley Fool October 2, 2007 Brian Orelli	PerkinElmer and ViaCell: A Bloody Good Deal? PerkinElmer buys umbilical cord storage company ViaCell for $300 million. Investors, take note; the merger may be a good fit for both companies.
The Motley Fool October 2, 2007 Billy Fisher	Closure for Bristol-Myers Bristol-Myers will pay $515 million to resolve cases from state and federal authorities alleging that the company promoted products for uses that hadn't been approved by the FDA.
The Motley Fool October 2, 2007 Brian Orelli	Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note.
<Older 4201-4210 Newer> Return to current articles.